Norway· NO-ID_BF682E87-475B-436F-B2BF-E30CA6BE6193
Xeomin
A botulinus toxin product containing clostridium botulinum neurotoxin type a (150kd), free of complexing proteins, registered in Norway by Merz Pharmaceuticals GmbH, Frankfurt, Tyskland. The same ATC class is registered in 11 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Botulinus toxin is registered in 11 of 19 countries.
Countries holding a registration under ATC M03AX01 (botulinus toxin), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Botulinus toxin · ATC M03AX01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
FEST (Norway)- Active substance
- Clostridium Botulinum Neurotoxin Type A (150kd), Free Of Complexing Proteins
- Manufacturer
- Merz Pharmaceuticals GmbH, Frankfurt, Tyskland
- Country
- Norway (NO)
- ATC code
- M03AX01
- ATC class
- Botulinus Toxin
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_BF682E87-475B-436F-B2BF-E30CA6BE6193
- no_varenummer093306100NOK 2270.2
- gtin4046222164423
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
55 interactions on record for botulinus toxin.
Graded by severity as the source publishes them — 11 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Botulinus toxin · interactions on record
55 records
- 11 severe
- 44 moderate
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- KanamycinA07AA08severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Botulinus toxin in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesBOTOXAllergan, Inc.
- FinlandAlluzienceIpsen Pharma
- SwitzerlandAlluzience, InjektionslösungIPSEN Pharma Schweiz GmbH
- CzechiaALLUZIENCEIPSEN PHARMA S.A.S., Paříž
- PolandAlluzienceIpsen Pharma
- BelgiumAlluzience 200 Speywood-Eenheden/mlIpsen Pharma
- SpainALLUZIENCE 200 UNIDADES SPEYWOOD/ML SOLUCION INYECTABLEIpsen Pharma
- FranceALLUZIENCE 200 unités Speywood/mL, solution injectableIPSEN PHARMA
Authorised across Europe · EMA
The same active substance is authorised in 1 EEA country. Names it is sold under:
- Germany · Alluzience, Bocouture
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c00b2ccb-2e4f-4f5e-9b98-ccab63b90bfb GET /v1/drugs/c00b2ccb-2e4f-4f5e-9b98-ccab63b90bfb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Pulver til injeksjonsvæske, oppløsning",
"source": "fest",
"status": "A",
"atc_name": "Botulinumtoksin",
"merkevare_id": "ID_BF682E87-475B-436F-B2BF-E30CA6BE6193",
"name_form_strength": "Xeomin pulv til inj væske, oppl 100 E",
"prescription_group": "C"
}See everything about botulinus toxin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.